vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Westrock Coffee Co (WEST). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $339.5M, roughly 1.8× Westrock Coffee Co). EXELIXIS, INC. runs the higher net margin — 40.8% vs -6.6%, a 47.5% gap on every dollar of revenue. On growth, Westrock Coffee Co posted the faster year-over-year revenue change (48.3% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $27.8M). Over the past eight quarters, Westrock Coffee Co's revenue compounded faster (32.8% CAGR vs 18.7%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Westrock Coffee Co is a global integrated coffee, tea and functional beverage solutions provider. It sources, roasts, manufactures and distributes coffee products, ready-to-drink beverages and custom formulations for retail, foodservice and commercial clients across North America and other key markets.
EXEL vs WEST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $339.5M |
| Net Profit | $244.5M | $-22.6M |
| Gross Margin | 95.6% | 11.5% |
| Operating Margin | 39.3% | -2.6% |
| Net Margin | 40.8% | -6.6% |
| Revenue YoY | 5.6% | 48.3% |
| Net Profit YoY | 74.8% | 8.3% |
| EPS (diluted) | $0.89 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $339.5M | ||
| Q3 25 | $568.3M | $354.8M | ||
| Q2 25 | $555.4M | $280.9M | ||
| Q1 25 | $566.8M | $213.8M | ||
| Q4 24 | — | $229.0M | ||
| Q3 24 | $539.5M | $220.9M | ||
| Q2 24 | $637.2M | $208.4M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $-22.6M | ||
| Q3 25 | $184.8M | $-19.1M | ||
| Q2 25 | $159.6M | $-21.6M | ||
| Q1 25 | $139.9M | $-27.2M | ||
| Q4 24 | — | $-24.6M | ||
| Q3 24 | $118.0M | $-14.3M | ||
| Q2 24 | $226.1M | $-17.8M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 11.5% | ||
| Q3 25 | 96.6% | 11.7% | ||
| Q2 25 | 96.5% | 14.7% | ||
| Q1 25 | 96.5% | 13.6% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | 96.8% | 16.8% | ||
| Q2 24 | 97.2% | 19.9% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | -2.6% | ||
| Q3 25 | 37.6% | -2.4% | ||
| Q2 25 | 33.6% | -5.3% | ||
| Q1 25 | 28.8% | -6.1% | ||
| Q4 24 | — | -4.3% | ||
| Q3 24 | 25.2% | -5.8% | ||
| Q2 24 | 43.3% | -7.9% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | -6.6% | ||
| Q3 25 | 32.5% | -5.4% | ||
| Q2 25 | 28.7% | -7.7% | ||
| Q1 25 | 24.7% | -12.7% | ||
| Q4 24 | — | -10.7% | ||
| Q3 24 | 21.9% | -6.5% | ||
| Q2 24 | 35.5% | -8.5% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $-0.22 | ||
| Q3 25 | $0.65 | $-0.20 | ||
| Q2 25 | $0.55 | $-0.23 | ||
| Q1 25 | $0.47 | $-0.29 | ||
| Q4 24 | — | $-0.26 | ||
| Q3 24 | $0.40 | $-0.16 | ||
| Q2 24 | $0.77 | $-0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $49.9M |
| Total DebtLower is stronger | — | $444.1M |
| Stockholders' EquityBook value | $2.2B | $-1.9M |
| Total Assets | $2.8B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $49.9M | ||
| Q3 25 | $791.1M | $34.0M | ||
| Q2 25 | $1.0B | $44.0M | ||
| Q1 25 | $1.1B | $33.1M | ||
| Q4 24 | — | $26.2M | ||
| Q3 24 | $1.2B | $22.4M | ||
| Q2 24 | $1.0B | $24.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $444.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $393.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $-1.9M | ||
| Q3 25 | $2.0B | $11.4M | ||
| Q2 25 | $2.1B | $18.2M | ||
| Q1 25 | $2.2B | $71.4M | ||
| Q4 24 | — | $97.5M | ||
| Q3 24 | $2.3B | $110.3M | ||
| Q2 24 | $2.1B | $81.5M |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $1.2B | ||
| Q3 25 | $2.7B | $1.2B | ||
| Q2 25 | $2.8B | $1.2B | ||
| Q1 25 | $2.9B | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $3.0B | $1.1B | ||
| Q2 24 | $2.8B | $1.1B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.03× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $36.7M |
| Free Cash FlowOCF − Capex | $332.4M | $27.8M |
| FCF MarginFCF / Revenue | 55.5% | 8.2% |
| Capex IntensityCapex / Revenue | 0.2% | 2.6% |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $-107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $36.7M | ||
| Q3 25 | $49.0M | $-26.6M | ||
| Q2 25 | $211.4M | $-7.0M | ||
| Q1 25 | $240.3M | $-22.1M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | $271.3M | $-332.0K | ||
| Q2 24 | $119.5M | $-23.7M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $27.8M | ||
| Q3 25 | $46.2M | $-44.7M | ||
| Q2 25 | $208.5M | $-27.5M | ||
| Q1 25 | $236.3M | $-63.4M | ||
| Q4 24 | — | $-15.4M | ||
| Q3 24 | $263.1M | $-36.7M | ||
| Q2 24 | $113.0M | $-59.9M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 8.2% | ||
| Q3 25 | 8.1% | -12.6% | ||
| Q2 25 | 37.5% | -9.8% | ||
| Q1 25 | 41.7% | -29.7% | ||
| Q4 24 | — | -6.7% | ||
| Q3 24 | 48.8% | -16.6% | ||
| Q2 24 | 17.7% | -28.7% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 2.6% | ||
| Q3 25 | 0.5% | 5.1% | ||
| Q2 25 | 0.5% | 7.3% | ||
| Q1 25 | 0.7% | 19.3% | ||
| Q4 24 | — | 7.9% | ||
| Q3 24 | 1.5% | 16.5% | ||
| Q2 24 | 1.0% | 17.4% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | — | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | 1.72× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.30× | — | ||
| Q2 24 | 0.53× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
WEST
| Coffee And Tea | $202.6M | 60% |
| Flavors Extracts And Ingredients | $69.6M | 21% |
| Sustainable Sourcing And Traceability Segments | $66.9M | 20% |
